Fosun Pharmaceutical (02196): FKC516 injection for recurrent or refractory B-cell non-Hodgkin lymphoma (r/RB-NHL) initiated phase II clinical trials in China

Zhitongcaijing · 2d ago

Zhitong Finance App News, Fosun Pharmaceutical (02196) announced that recently, Fosun Carey (Shanghai) Biotechnology Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), initiated phase II clinical trials on FKC516 injection (hereinafter referred to as “FKC516”) for recurrent or refractory B-cell non-Hodgkin lymphoma (r/RB-NHL) in China.

FKC516 is a CD20 autologous CAR-T cell therapy product approved by the Group (that is, the Company and its holding subsidiaries/units, the same below). The Group has exclusive rights to develop and commercialize this product in all disease fields worldwide according to the agreement (which mainly includes).

As of September 2026, the Group's cumulative R&D investment for FKC516 at this stage is approximately RMB 13.37 million (including licensing fees; unaudited).

As of the date of this announcement (i.e. November 12, 2026), no CAR-T products with the same target have been approved for marketing in China.